Dr. Reddy's Laboratories has launched Avigan (Favipiravir) 200 mg Tablets in India. The launch is part of the global licensing agreement with Fujifilm Toyama Chemical Co. that grants Dr. Reddy’s the exclusive rights to manufacture, sell and distribute Avigan (Favipiravir) 200 mg Tablets in India.
Avigan (Favipiravir) has been approved by the Drugs Controller General of India (DCGI) for the treatment of patients with mild to moderate COVID-19 disease. Dr. Reddy’s Avigan comes in a complete therapy pack of 122 tablets with a two-year shelf life.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
